Why HealthEquity Stock Belongs in Your Portfolio: 5 Compelling Reasons

HealthEquity controls roughly 40% of the U.S. Health Savings Account market. As of Q3 2024, the company administers 7.3 million HSA accounts holding $42 billion in assets. That's not marginal positioning—it's functional monopoly status in a corridor that Wall Street largely ignores.

The HSA market expands faster than traditional healthcare spending. High-deductible health plans (HDHPs) now cover 32% of American workers, up from 26% five years ago. The trend accelerates as employers shift cost responsibility downstream. HealthEquity profits directly from enrollment growth without building new infrastructure. Their platform already handles the volume.

Competitors are fragmented. PayFlex, Fidelity, and Lively capture smaller slices. None possess HealthEquity's scale advantages or integrated custodial/record-keeper dual role. Switching costs for employers and employees are substantial, creating durable competitive moats.

Revenue grew 22% year-over-year in FY2024 to $267 million. More relevant: HealthEquity's adjusted operating margin expanded to 31%. That's venture-scale profitability in a regulated business. Healthcare software typically trades at 8-12x revenue multiples. HealthEquity's current valuation sits near 4-5x revenue—a substantial discount reflecting general market confusion about its defensive characteristics.

Free cash flow conversion matters for long-term holders. The company generates cash from day-one account onboarding, since HSA custodians collect fees upfront. In 2024, HealthEquity produced $47 million in free cash flow on $185 million in operating income. That 25% conversion ratio is legitimately strong for a growth company operating in regulated healthcare.

Asset-based revenue drives predictable recurring income. When an employer signs a 3-5 year contract, HealthEquity typically captures: custodial fees (per-account charges), asset-based fees (0.30-0.50% of AUM), and transaction fees. Three revenue streams from one customer relationship reduce customer acquisition payback periods to 18-24 months.

Employer adoption lags consumer awareness. Only 27% of workers with HSA-eligible plans actively contribute to HSAs. The remaining 73% leave money on the table—literally tax-advantaged dollars sitting unused. When adoption normalizes toward 50%, account growth accelerates independently of HDHP enrollment.

HSAs offer a tax advantage that no other account provides: triple tax-free withdrawals for qualified medical expenses. Contributions reduce taxable income. Growth is tax-free. Withdrawals for healthcare are tax-free. Over 30 years, an HSA grows larger than a 401(k) for many households, yet receives a fraction of the attention and capital.

Individual contributors are gaining share. In 2023, 3.2 million people opened individual HSA accounts, up 18% from 2022. HealthEquity captured the bulk through its retail channel. As financial advisors increasingly recommend HSAs for retirement planning, HealthEquity becomes the infrastructure beneficiary. The company owns the largest consumer brand in the space.

HealthEquity operates with obvious margin expansion runway. Today's 31% adjusted operating margin reflects 2024's service delivery costs. Scaling benefits exist across customer service, technology infrastructure, and compliance. Management targets 40% margins by 2027. With flat revenue growth from that point, margin expansion alone drives 30%+ earnings growth.

The Careables acquisition (completed 2023) added consumer health benefits. This subsidiary generated $28 million in revenue in 2024, with integration still incomplete. Careables brings 2.1 million unique users and a telehealth/discount benefits model that cross-sells to HealthEquity's HSA base. Initial projections suggest Careables can reach $100+ million in standalone revenue, expanding the parent's addressable market beyond HSA administration.

International expansion remains untapped. Canada, UK, and Australia operate similar tax-advantaged health account structures without dominant platforms. Management has explicitly identified international as a multi-year opportunity. Each market represents 20-30% the size of the U.S. Opportunity. Early moves cost little, while success would unlock significant upside.

Forward estimates assume $385-400 million in 2025 revenue, implying 45-50% compounded growth from 2024. At current trading prices ($60-70 range as of late 2024), HealthEquity trades at roughly 1.0-1.2x forward sales. Comparable SaaS businesses trade at 2-3x. Even accounting for healthcare's regulatory complexity, the discount is substantial.

Earnings yield matters for value-conscious investors. Using conservative 2025 earnings estimates of $1.20-1.40 per share, the stock yields a 2-2.3% earnings yield at $65. Add 22% revenue growth visibility and 30-40% margin expansion potential, and the total return framework becomes visible. A reasonable 5-year price target is $130-150, implying 15-18% annualized returns from current levels.

Downside protection exists through cash generation. HealthEquity carries $180 million in net cash (as of Q3 2024) with no meaningful debt. The balance sheet can absorb macro shocks. Dividend initiation is plausible within 24 months if management prioritizes shareholder returns. A 1-2% dividend would further support valuations in rate-cut environments.

HealthEquity's revenue demonstrates minimal sensitivity to recessions. During 2020-2021, despite unemployment spikes, HSA account growth accelerated. Individuals with job loss often retain HSA balances and contribute from severance. Employer HDHP adoption increased during downturns as plan sponsors reduced premium costs. The business is counter-cyclical in revenue growth, if not profits.

Correlation with tech volatility is low. HealthEquity trades on healthcare fundamentals, not AI hype cycles or SaaS growth multiple compression. During 2022-2023's software downturn, HealthEquity shares declined modestly while peers fell 60-70%. Defensive positioning combined with genuine growth creates portfolio ballast that reduces volatility.

Dividend growth potential provides another layer of portfolio utility. Once management establishes a dividend (likely 2026), the stock transitions from pure growth to hybrid growth-and-income. Long-term holders benefit from compounding dividend increases while capturing HSA market share expansion. Few healthcare IT names offer this trajectory.

Regulatory risk is real. HSA rules are set by IRS and Treasury. Changes to contribution limits, eligible expenses, or account structures would directly impact HealthEquity's addressable market. Bipartisan support for HSAs exists, but policies shift. A sudden expansion (e.g., allowing HSA funds for insurance premiums) could accelerate growth or fragment the market. Monitor legislative calendars.

Competition from banks and custodians persists. Large custodians like Fidelity and Schwab use HSAs as customer acquisition tools, pricing below profitability to capture assets. If a major player decides to prioritize HSA growth, HealthEquity's market share and pricing power face pressure. Fidelity's entrance into retail HSAs in 2022 was notable, though market share capture has been limited so far.

Growth deceleration is inevitable at scale. Current 22-25% annual growth rates cannot sustain indefinitely. Within five years, revenue approaches $500 million, creating a larger base. Mature-phase growth (10-15% annually) is still respectable but requires investor perspective reset. Stock may underperform during transition years as growth expectations compress.

Integration execution risk from Careables acquisition remains. Cross-selling synergies are assumed in current valuations. If Careables retention rates deteriorate or growth stalls, the $200+ million acquisition price looks expensive. Monitor quarterly Careables metrics closely for signs of difficulty.

Define position size based on your risk tolerance. Growth-oriented investors (40+ years to retirement) might allocate 2-4% of growth portfolios to HealthEquity. Conservative allocators should target 0.5-1.5%, treating it as a satellite position. The stock is neither a core holding nor a speculative gamble at current valuations.

Set purchase targets during normal volatility. Healthcare stocks experience 15-25% drawdowns within bull markets. Accumulate shares in tranches at $55, $50, and $45 rather than buying aggressively into rallies. Dollar-cost averaging into HealthEquity reduces timing risk.

Monitor quarterly metrics obsessively. Track: new account growth (target: 12%+ YoY), assets under administration growth (target: 15%+), revenue per account (target: flat to +3% YoY), and gross margins (target: 60%+). Deviations signal emerging problems. Review earnings transcripts for management commentary on competitive dynamics and regulatory changes.

Reassess position every 18 months. Valuations compound rapidly in growth businesses. A $65 stock target becomes $130 within 5 years of 15% annual returns. At that point, position sizing and conviction should be revisited. Some holders will trim profits. Others will hold for compounding. Neither approach is wrong—it's a personal decision based on opportunity cost and portfolio goals.